A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)

Inclusion Criteria: * Subject is 18 years of age or older. * Subject has never been treated with cisplatin and is to receive first course of cisplatin-based chemotherapy (\>=70 mg/m\^2). * Subject has a Karnofsky performance score of \>=60. * Subject has a predicted life expectancy of \>=3 months. * Subject has adequate bone marrow, kidney, and liver function as evidenced by: * Absolute neutrophil count \>=1,500/mm3 and white blood cell count \>=3,000/mm3. * Platelet count \>=100,000/mm3. * Aspartate aminotransferase (AST) \<=2.5 x upper limit of normal (ULN) range. * Alanine aminotransferase (ALT) \<=2.5 x ULN. * Bilirubin \<=1.5 x ULN, except for subjects with Gilbert's syndrome. * Creatinine \<=1.5 x ULN. * Subject is able to read, understand, and complete the questionnaires. Exclusion Criteria: * Any current treatment or medical history (eg, subject is mentally incapacitated or has a psychiatric disorder) that, in the opinion of the investigator, would confound the results of the study or pose any unwarranted risk in administering study drug to the subject. * Subject has contraindication to the administration of cisplatin, ondansetron, or dexamethasone including, but not limited to, a history of hypersensitivity to the drugs or their components, severe renal impairment, severe bone marrow suppression, hearing impairment, or systemic fungal infection. * Subject is scheduled to receive any other chemotherapeutic agent with an emetogenicity level of 3 or above (Hesketh Scale) from Day -2 through Day 6. * Subject is scheduled to receive any radiation therapy to the abdomen or pelvis within 5 days prior to and/or during Days 1 through 5 following cisplatin infusion. * Subject has symptomatic primary or metastatic central nervous system (CNS) disease. * Subject has ongoing vomiting caused by any etiology or has a history of anticipatory nausea and vomiting.